The post Will Ethereum reclaim its highs? 3 reasons why whale execution is bullish appeared on BitcoinEthereumNews.com. Despite a broad crypto pullback, aggressiveThe post Will Ethereum reclaim its highs? 3 reasons why whale execution is bullish appeared on BitcoinEthereumNews.com. Despite a broad crypto pullback, aggressive

Will Ethereum reclaim its highs? 3 reasons why whale execution is bullish

Despite a broad crypto pullback, aggressive Ethereum accumulation has continued as large buyers step in during weakness rather than retreating. 

On-chain data from Lookonchain showed Tom Lee’s Bitmine absorbing nearly 45,000 ETH in rapid succession, sourcing liquidity directly from Kraken and BitGo. 

At the same time, an OTC-linked whale added another 10,000 ETH even as broader sentiment weakened. 

This behavior signals intent. Instead of waiting for confirmation, large players appear willing to absorb downside volatility. 

However, accumulation alone does not guarantee immediate upside. Therefore, the structure of spot demand, order behavior, and leverage positioning now matters more than price reactions.

Large buyers absorb sell pressure

Spot taker CVD continued to print buyer dominance, reinforcing the idea that aggressive participants control execution at market prices. 

Buyers do not wait on bids; instead, they cross the spread and absorb available supply. This pattern suggested urgency rather than caution. 

Furthermore, buyer-dominant CVD during a market drawdown often reflects conviction rather than speculative chasing. However, this demand does not come from scattered retail flows. Large executions dominate activity. 

As a result, the Spot market showed clear absorption rather than distribution. Still, sustained buyer aggression must persist to offset broader risk-off conditions. 

Otherwise, sellers could regain short-term control. Therefore, spot taker behavior now acts as the primary stabilizing force for Ethereum’s [ETH] price structure.

Source: CryptoQuant

Ethereum order sizes reveal whale execution

Spot Average Order Size has expanded sharply, pointing directly toward whale-driven participation rather than fragmented retail activity. 

Larger order sizes usually reflect institutional desks or OTC-linked execution strategies. In this case, order growth aligns closely with the accumulation flows identified on-chain. 

The alignment matters. It shows consistency between wallet-level behavior and exchange-level execution. 

However, whales do not chase price blindly. They typically scale into positions while liquidity remains available. Therefore, rising order size during weakness suggests deliberate accumulation rather than panic buying. 

At the same time, sustained large orders can compress the available supply. The compression would increase sensitivity to future demand spikes. 

Hence, order size now reinforces the broader accumulation narrative already visible on-chain.

Source: CryptoQuant

Leverage builds as confidence grows

Funding Rates have risen sharply, signaling that traders increasingly favor long exposure. The metric sat around 0.01017, marking a 145.56% increase over the recent baseline. 

Traders now pay a clear premium to maintain long positions. This shift reflects growing confidence rather than hesitation. 

However, leverage behaves differently from spot demand. While spot buyers absorb supply outright, leveraged traders rely on price continuation. 

Therefore, elevated funding strengthens upside pressure only if the price holds steady. If momentum stalls, funding costs could force faster unwinds. 

Furthermore, rapid funding expansion often increases short-term volatility. As a result, leverage now adds fuel to Ethereum’s structure but also raises sensitivity to abrupt pullbacks.

Source: CryptoQuant

Can accumulation stabilize Ethereum?

Ethereum’s structure favored stabilization rather than breakdown. Large buyers continue absorbing supply, Spot demand remains aggressive, and whale-sized executions dominate flows. 

However, rising leverage introduces conditional risk. If spot accumulation persists, it would likely anchor the price and limit downside volatility. If Spot demand fades, leverage could magnify weakness. 

Therefore, Ethereum’s near-term direction hinges less on sentiment and more on whether aggressive buyers continue absorbing supply under pressure.


Final Thoughts

  • Large players appear comfortable absorbing volatility rather than waiting for confirmation.
  • Leverage adds upside potential but could amplify moves if spot demand weakens.

Next: Solana absorbs 98K SOL sell-off – Why price refuses to break

Source: https://ambcrypto.com/will-ethereum-reclaim-its-highs-3-reasons-why-whale-execution-is-bullish/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26